Skip to main content

Neal Shore, MD, FACS

Neal Shore, MD, FACS.
Videos
01/18/2024
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses...
01/18/2024
Journal of Clinical Pathways
Neal Shore, MD, Carolina Urologic Research Center
Conference Coverage
01/26/2024
Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.
Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.
Neal Shore, MD, discusses...
01/26/2024
Oncology